HOXA4 and B-cell chronic lymphocytic leukemia: We observed significantly higher levels of apoptosis at both drug concentrations in primary CLL cells expressing HOXA4 in comparison to control cells (P = 0.02 and P < 0.01, respectively, Fig. 4e), confirming that re-expression of HOXA4 increases drug sensitivity in primary CLL cells.